Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA

RNAi technology is taking strong position among the key therapeutic modalities, with dozens of siRNA-based programs entering and successfully progressing through clinical stages of drug development. To further explore potentials of RNAi technology as therapeutics, we engineered and tested VEGFR2 siR...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Liu, Xiaoxia, Wang, Wei, Samarsky, Dmitry, Liu, Li, Xu, Qian, Zhang, Wenqing, Zhu, Guangzu, Wu, Ping, Zuo, Xialin, Deng, Houliang, Zhang, Jingjing, Wu, Zhuomin, Chen, Xiaohui, Zhao, Lingfeng, Qiu, Zhiyong, Zhang, Zhongyi, Zeng, Qiyi, Yang, Wei, Zhang, Biliang, Ji, Aimin
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2014
Aiheet:
RNA
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4191406/
https://ncbi.nlm.nih.gov/pubmed/25223783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nar/gku831
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia